Clinical trial
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
NCT00477529 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00477529 |
|---|---|
| Title | ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer |
| Official title | A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hormone Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | ABI-008 |
| Enrollment | 102 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 2, 2011 |
| Completion | Jun 2, 2011 |
| First posted | May 23, 2007 |
| Last update posted | Nov 22, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: